AKT1 and neoplasm: Some approaches in recent years include novel tyrosine kinases with the subsequent inhibition of intracellular signaling (PI3K/AKT/mTOR and CDK4/6 inhibitors), as well as other newer approaches that are in the design process to attack other tumor weaknesses.